AlphaFold predicted structure
OAS1 · P00973
Mean pLDDT
83.9/ 100
Confident
400 residues
Confidence breakdown
- Very high(≥ 90)67%
- Confident(70–90)17%
- Low(50–70)3%
- Very low(< 50)13%
Open interactive 3D viewer
AlphaFold (Jumper et al., 2021) · CC BY 4.0
OAS1
Chr 12q24.132'-5'-oligoadenylate synthetase 1
- Aliases:
- OIASI, IFI-4
- MANE:
- ENST00000202917.10
Annotations refreshed 1 month ago.
Predicted protein structure
Clinical relevance (Genomics England PanelApp)
Diagnostic Grade (Green)
Childhood interstitial lung disease
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedCOVID-19 research
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownPrimary immunodeficiency or monogenic inflammatory bowel disease
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown
Disease associations (Open Targets)
pulmonary alveolar proteinosis with hypogammaglobulinemia
0.71COVID-19
0.57respiratory failure
0.33neurodegenerative disease
0.32middle ear disorder
0.30Abnormal mastoid morphology
0.30spinal cord injury
0.29age-related macular degeneration
0.28systemic lupus erythematosus
0.27osteoarthritis
0.25
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Protein function (UniProt)
2'-5'-oligoadenylate synthase 1
Interferon-induced, dsRNA-activated antiviral enzyme which plays a critical role in cellular innate antiviral response (PubMed:34581622). In addition, it may also play a role in other cellular processes such as apoptosis, cell growth, differentiation and gene regulation. Catalyzes the formation of 2'-5'-oligoadenylates (2-5A) from polymerization of ATP which then bind to the inactive monomeric form of ribonuclease L (RNase L) leading to its dimerization and subsequent activation. Activation of RNase L leads to degradation of cellular as well as viral RNA, resulting in the inhibition of protein synthesis, thus terminating viral replication (PubMed:34145065, PubMed:34581622, PubMed:40010341). Involved in intercellular immune signaling that limits local spread of RNA virus infection and protects against tumorigenesis (PubMed:40010341). Can generate high levels of 2',5'-oligoadenylates in transformed cells, targeting them to innate and adaptive immunesurveillance mechanisms (PubMed:40010341). Can mediate the antiviral effect via the classical RNase L-dependent pathway or an alternative antiviral pathway independent of RNase L. The secreted form displays antiviral effect against vesicular stomatitis virus (VSV), herpes simplex virus type 2 (HSV-2), and encephalomyocarditis virus (EMCV) and stimulates the alternative antiviral pathway independent of RNase L
Diseases associated with OAS1
Curated MONDO disease pages that list OAS1 among their top associated genes.